Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale

What Was Tested

This clinical study looks at Tirzepatide.

The primary objective is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to buprenorphine on retention and on substance-related and sleep outcomes in adults with OUD.

Why It Was Studied

Buprenorphine does not always eliminate illicit opioid use and craving and does not treat stimulant or other substance co-use, nor common comorbid sleep problems.

Tirzepatide, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, may help address substance use and sleep problems.

Who Took Part

The abstract describes 310 adults taking part.

The age groups tagged for this paper are adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Neither the adults nor the staff measuring them knew who was on Tirzepatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.

Running at several centres spread the Tirzepatide study over different clinics and patient groups.

What Was Measured

The National Drug Abuse Treatment Clinical Trials Network (CTN) is conducting a 9-site outpatient, intent-to-treat, two-arm, double-blind, randomized controlled trial: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of OUD (TAB).

The primary outcome is 6-month buprenorphine treatment retention.

Topics PubMed links to this paper include Tirzepatide, Buprenorphine, Opioid-Related Disorders, Randomized Controlled Trials as Topic and Analgesics, Opioid.

The authors tagged it with the keywords GLP-1 and Retention.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 310 adults.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2026 (Contemporary clinical trials), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.